“[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]” (2016) Farmeconomia. Health economics and therapeutic pathways, 17(2), pp. 67–80. doi:10.7175/fe.v17i2.1251.